Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Shares Outstanding (Weighted Average) (2023 - 2026)

ArriVent BioPharma has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $45.1 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $45.1 million for Q1 2026, up 32.95% from a year ago — trailing twelve months through Mar 2026 was $45.1 million (up 32.95% YoY), and the annual figure for FY2025 was $38.5 million, up 22.22%.
  • Shares Outstanding (Weighted Average) reached $45.1 million in Q1 2026 per AVBP's latest filing, up from $38.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $45.1 million in Q1 2026 and bottomed at $1.3 million in Q1 2023.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $31.5 million (2024), compared with a mean of $24.4 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) skyrocketed 1945.79% in 2024 before it increased 2.85% in 2025.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $2.1 million in 2023, then skyrocketed by 1369.88% to $31.5 million in 2024, then grew by 22.22% to $38.5 million in 2025, then grew by 17.17% to $45.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AVBP at $45.1 million in Q1 2026, $38.5 million in Q4 2025, and $37.0 million in Q3 2025.